[The clinico-immunological evaluation of the ribomunyl treatment of chronic bronchitis patients]. / Kliniko-immunologicheskaia otsenka lecheniia ribomunilom bol'nykh khronicheskim bronkhitom.

ABSTRACT

The paper reports the results of ribomunil trial in chronic bronchitis (CB) patients who suffered from frequent exacerbations. The drug was found to act primarily on a phagocytic component of the immunity and local immunity of the respiratory mucosa. Because of its vaccine-like effect, ribomunil administration is most beneficial in CB remission. Ribomunil treatment results in reduction of the number and duration of CB exacerbations, of the scope of antibacterial therapy.